← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Theragnostic Technologies, Inc.
Coram, NY
$3,642,234
Total funding
5
Grants
Funding over time
peak $771K · FY2013–19$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,642,234 · 5
By mechanism
R44$2,984,964 · 2
R43$496,777 · 2
R41$160,493 · 1
Investigators at Theragnostic Technologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent For Diagnosis of Renal Failure$770,967
R44 · FY2015 · DK
A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy$748,000
R44 · FY2018 · DK
A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy$748,000
R44 · FY2019 · DK
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent For Diagnosis of Renal Failure$717,997
R44 · FY2016 · DK
CRISPR-Cas9 Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens$306,277
R43 · FY2017 · AI
A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy$160,500
R43 · FY2017 · DK
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti$160,493
R41 · FY2013 · DK
A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy$30,000
R43 · FY2017 · DK